Quell has been established with the aim of developing engineered T regulatory (Treg) cell therapies. Tregs are a subset of T cells with the potential to downregulate the immune system. Quell will seek to utilise the power of Treg cells to advance therapies for the management and treatment of a range of conditions such as solid organ transplant rejection, autoimmune and inflammatory diseases.
Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases.
Quell was founded by Syncona, a FTSE 250 healthcare company, which has committed £34 million to the business in a £35 million Series A financing, with a further £1 million being contributed by UCL Technology Fund.
We are hiring. email@example.com